secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019161
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q1 net loss $17.3M; cash $150.4M; RLYB212 data expected Q4 2023
------------------------------------------------------------------------

- Net loss $17.3M ($0.43 per share) vs $14.5M ($0.48) in Q1 2022.
- Cash, cash equivalents and marketable securities $150.4M as of March 31, 2023; runway into Q1 2025.
- RLYB212 multiple dose cohort initiated; Phase 1b data to be presented at ISTH June 2023; cohort data expected Q4 2023.
- RLYB116 multiple ascending dose study ongoing; initial safety, PK and PD data expected Q4 2023.
- Research collaboration with EyePoint announced for sustained intraocular delivery of C5 inhibitor targeting geographic atrophy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017023019161/0000950170-23-019161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017023019161/rlyb-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer